Cellectar Biosciences, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Cellectar Biosciences, Inc. (CLRB) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$4.61 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-04
- Cellectar Biosciences, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$4.61M.
- Cellectar Biosciences, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$9.36M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$4.61M 10-K · filed 2026-03-04 |
| 2024-12-31 | -$9.36M 10-K · filed 2026-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |